Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress [Seeking Alpha]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Seeking Alpha
RYTM's IMCIVREE awaits FDA label expansion for acquired hypothalamic obesity, with the PDUFA date extended to March 20, 2026, after a major filed amendment. Upcoming Q4 2025 phase 2 data for IMCIVREE in Prader-Willi Syndrome and positive Bivamelagon results for acquired hypothalamic obesity offer additional catalysts and shots on goal. The Prader-Willi Syndrome market in the 7 major markets is expected to reach $1.30 billion by 2032. Volodymyr Kalyniuk/iStock via Getty Images The last time I spoke about Rhythm Pharmaceuticals, Inc. RYTM ) it was in a Seeking Alpha article entitled "Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder." With respect to this article, I More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscrib
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.MarketBeat
- Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $105.00 to $114.00. They now have a "buy" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025GlobeNewswire
RYTM
Earnings
- 11/4/25 - Miss
RYTM
Sec Filings
- 11/24/25 - Form 4
- 11/20/25 - Form 144
- 11/14/25 - Form SCHEDULE
- RYTM's page on the SEC website